Monopar Therapeutics Inc 1IY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €0.84
- Day Range
- €0.79–0.86
- 52-Week Range
- €0.26–7.90
- Bid/Ask
- €0.82 / €0.86
- Market Cap
- €13.81 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
- Website
- https://www.monopartx.com
Valuation
Metric
|
1IY
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.11 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
1IY
|
---|---|
Quick Ratio | 6.13 |
Current Ratio | 6.21 |
Interest Coverage | — |
Quick Ratio
1IY
Profitability
Metric
|
1IY
|
---|---|
Return on Assets (Normalized) | −62.30% |
Return on Equity (Normalized) | −80.35% |
Return on Invested Capital (Normalized) | −86.12% |
Return on Assets
1IY
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Dyffscxjr | Ymdwc | $635.4 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Tglhfqvs | Bxwdryz | $124.1 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Ycjrxbn | Dmpmmf | $114.2 Bil | |||
Moderna Inc
MRNA
| Swybqnr | Svqr | $53.7 Bil | |||
argenx SE ADR
ARGX
| Vmyszdrr | Ymgfs | $23.0 Bil | |||
BioNTech SE ADR
BNTX
| Gqcdddcb | Cfp | $22.2 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Tdmnnbwv | Trbcfl | $20.3 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Fdvnvytw | Hwmsbxc | $15.9 Bil | |||
United Therapeutics Corp
UTHR
| Dngzxwjy | Qnw | $12.8 Bil | |||
Incyte Corp
INCY
| Yczldds | Tlfmfvn | $12.2 Bil |